Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
Business Wire•14/10/2026•07:00 ET
0
Key Highlights
- ➤Pulse Biosciences partners with Clayman Thyroid Center for commercial and clinical use
- ➤Vybrance System now treats symptomatic benign thyroid nodules at Tampa center
- ➤Collaboration will generate real-world outcomes and formal clinical study data
- ➤Clayman center is Tampa Bay’s only site offering nPulse technology for nodules
Expert Statements
Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences
“The Clayman Thyroid Center is one of the largest thyroid surgery centers across the country with significant regional and national referral patterns”
Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences
“This partnership allows expansion of access to nPulse Vybrance technology for patients to be treated in a high-volume center and a visionary clinical partner generating rigorous outcomes data. That combination will be invaluable as we build the foundation for expanded access to the Vybrance System.”
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
Collaboration adds the nPulse™ Vybrance™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical data
Get started
Create a free account to read the full story.